Qrons Inc. (QRON) Financial Statements (2024 and earlier)
Company Profile
Business Address |
28-10 JACKSON AVENUE, #26N LONG ISLAND CITY, NY 11101 |
State of Incorp. | WY |
Fiscal Year End | December 31 |
Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 3,069 | 35,065 | 57,632 | 67,025 | 143,862 | 57,767 | |||
Cash and cash equivalents | 3,069 | 35,065 | 57,632 | 67,025 | 143,862 | 57,767 | |||
Prepaid expense | 56,265 | 51,985 | 15,812 | ||||||
Total current assets: | 3,069 | 35,065 | 57,632 | 123,290 | 195,847 | 73,579 | |||
Noncurrent Assets | |||||||||
Prepaid expense | 25,000 | 25,000 | |||||||
Other undisclosed noncurrent assets | (25,000) | (25,000) | |||||||
TOTAL ASSETS: | 3,069 | 35,065 | 57,632 | 123,290 | 195,847 | 73,579 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 128,285 | 90,976 | 49,059 | 140,967 | 23,324 | 14,141 | |||
Other undisclosed accounts payable and accrued liabilities | 128,285 | 90,976 | 49,059 | 140,967 | 23,324 | 14,141 | |||
Debt | 308,247 | 266,685 | 168,636 | 131,171 | 25,000 | 6,665 | |||
Derivative instruments and hedges, liabilities | 358,775 | 405,957 | 154,485 | 89,367 | 36,827 | 31,090 | |||
Due to related parties | ✕ | 15,234 | 50,000 | 50,000 | 50,000 | 3,421 | 1,410 | ||
Other undisclosed current liabilities | 471,810 | 324,192 | 329,768 | 219,907 | |||||
Total current liabilities: | 1,282,351 | 1,137,810 | 751,948 | 631,412 | 88,572 | 53,306 | |||
Noncurrent Liabilities | |||||||||
Total liabilities: | 1,282,351 | 1,137,810 | 751,948 | 631,412 | 88,572 | 53,306 | |||
Equity | |||||||||
Equity, attributable to parent | (1,279,282) | (1,102,745) | (694,316) | (508,122) | 107,275 | 20,273 | |||
Preferred stock | 2 | 2 | 2 | 2 | 2 | 2 | |||
Common stock | 1,344 | 1,329 | 1,329 | 1,309 | 1,287 | 1,240 | |||
Additional paid in capital | 8,254,316 | 7,697,351 | 7,037,796 | 6,561,047 | 5,629,694 | 1,611,711 | |||
Accumulated deficit | (9,534,944) | (8,801,427) | (7,733,443) | (7,070,480) | (5,523,708) | (1,592,680) | |||
Total equity: | (1,279,282) | (1,102,745) | (694,316) | (508,122) | 107,275 | 20,273 | |||
TOTAL LIABILITIES AND EQUITY: | 3,069 | 35,065 | 57,632 | 123,290 | 195,847 | 73,579 |
Income Statement (P&L) (USD)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
---|---|---|---|---|---|---|---|---|
Cost of revenue (Cost of Goods and Services Sold) | (35,219) | (33,781) | (1,438) | |||||
Other undisclosed gross profit | ||||||||
Gross profit: | (35,219) | (33,781) | (1,438) | |||||
Operating expenses | (629,629) | (801,952) | (553,741) | (1,516,432) | (3,904,945) | (1,403,145) | ||
Other undisclosed operating income (loss) | 35,219 | 33,781 | 1,438 | |||||
Operating loss: | (629,629) | (801,952) | (553,741) | (1,516,432) | (3,904,945) | (1,403,145) | ||
Nonoperating expense | (103,888) | (266,032) | (109,222) | (30,340) | (26,083) | (20,295) | ||
Other nonoperating expense | ||||||||
Interest and debt expense | (135,654) | (208,892) | (52,019) | (42,574) | (20,346) | (14,205) | ||
Loss from continuing operations: | (869,171) | (1,276,876) | (714,982) | (1,589,346) | (3,951,374) | (1,437,645) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | (1,276,876) | (714,982) | (1,589,346) | (3,951,374) | (1,437,645) | |
Other undisclosed net loss | ||||||||
Net loss: | (869,171) | (1,276,876) | (714,982) | (1,589,346) | (3,951,374) | (1,437,645) | ||
Other undisclosed net income attributable to parent | 135,654 | 208,892 | 52,019 | 42,574 | 20,346 | 14,205 | ||
Net loss available to common stockholders, basic: | (733,517) | (1,067,984) | (662,963) | (1,546,772) | (3,931,028) | (1,423,440) | ||
Interest on convertible debt | 4,973 | |||||||
Other undisclosed net income available to common stockholders, diluted | ||||||||
Net loss available to common stockholders, diluted: | (728,544) | (1,067,984) | (662,963) | (1,546,772) | (3,931,028) | (1,423,440) |
Comprehensive Income (USD)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (869,171) | (1,276,876) | (714,982) | (1,589,346) | (3,951,374) | (1,437,645) | ||
Comprehensive loss, net of tax, attributable to parent: | (869,171) | (1,276,876) | (714,982) | (1,589,346) | (3,951,374) | (1,437,645) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.